Figure 7. In vivo cytoplasmic delivery of [pIC] using invivo jetPEI decreases human pancreatic tumor growth in subcutaneous and quasi-orthotopic models.
(A) Mice were injected subcutaneously with MIA PaCa-2 cells (5 × 106) and once tumors reached ~75 mm3 they were divided into 4 groups. Each group was treated with 4 doses of [pIC], PEI or [pIC]PEI (1 mg/kg) as indicated in the schematic. One set of mice (5 mice from each group) were sacrificed 3 days after the last dose of [pIC]PEI. The other group was continued until the control tumors reached the IACUC end point (1250 mm3). (B) Tumor weights were measured and presented graphically. Mean of the tumor weights of each group of mice was shown in line graph. * p<0.01 vs Control. (C) Tumor volumes were measured periodically using a vernier caliper and presented graphically. (D) MIA PaCa-2-luc cells (5 × 106) were injected intra-peritoneally into nude mice. BLI was performed every week after tumor cell implantation. After 2 weeks following cell implantation, mice were divided into two groups of 10 mice each. One group was used as control, without treatment, and the other group was injected twice weekly with [pIC]PEI (1mg/Kg) intra-peritoneally (total 4 doses). Control and treated mice were observed for tumor progression using BLI. Once the mice were sacrificed, the pancreas was weighed and data presented graphically. * p<0.01 vs Control.